MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
516.56
+3.35
+0.65%
After Hours: 516.56 0 0.00% 19:30 09/25 EDT
OPEN
513.75
PREV CLOSE
513.21
HIGH
523.96
LOW
511.31
VOLUME
153.39K
TURNOVER
--
52 WEEK HIGH
615.00
52 WEEK LOW
393.61
MARKET CAP
11.93B
P/E (TTM)
-40.1358
1D
5D
1M
3M
1Y
5Y
1D
HCA, Tenet, CoreWeave, Microsoft, Madrigal Trending With Analysts
TipRanks · 20h ago
How New Headquarters Opening At Madrigal Pharmaceuticals (MDGL) Has Changed Its Investment Story
Simply Wall St · 1d ago
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Seeking Alpha · 2d ago
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs
Dow Jones · 2d ago
Goldman Sachs Reinstates Buy on Madrigal Pharmaceuticals, Announces $704 Price Target
Benzinga · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Madrigal Pharmaceuticals (MDGL)
TipRanks · 2d ago
Madrigal Pharmaceuticals Price Target Announced at $725.00/Share by Citigroup
Dow Jones · 3d ago
Madrigal Pharmaceuticals Initiated at Buy by Citigroup
Dow Jones · 3d ago
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.